These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 23028623)

  • 21. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
    Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
    BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
    Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
    Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.
    Chaivichacharn P; Avihingsanon A; Gatechompol S; Ubolyam S; Punyawudho B
    Drug Metab Pharmacokinet; 2022 Dec; 47():100478. PubMed ID: 36375225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
    Foglia E; Bonfanti P; Rizzardini G; Bonizzoni E; Restelli U; Ricci E; Porazzi E; Scolari F; Croce D
    PLoS One; 2013; 8(2):e57777. PubMed ID: 23460905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
    Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D
    Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
    d'Arminio Monforte A; Gianotti N; Cozzi-Lepri A; Pinnetti C; Andreoni M; di Perri G; Galli M; Poli A; Costantini A; Orofino G; Maggiolo F; Mazzarello G; Celesia BM; Luciani F; Lazzarin A; Sighinolfi L; Rizzardini G; Bonfanti P; Perno CF; Antinori A;
    Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
    Decloedt EH; McIlleron H; Smith P; Merry C; Orrell C; Maartens G
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3195-200. PubMed ID: 21537021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
    Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
    Foissac F; Urien S; Hirt D; Frange P; Chaix ML; Treluyer JM; Blanche S
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4320-5. PubMed ID: 21746952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.
    Chabala C; Turkova A; Kapasa M; LeBeau K; Tembo CH; Zimba K; Weisner L; Zyambo K; Choo L; Chungu C; Lungu J; Mulenga V; Crook A; Gibb D; McIlleron H;
    Pediatr Infect Dis J; 2023 Oct; 42(10):899-904. PubMed ID: 37506295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
    Cooper C; la Porte C; Tossonian H; Sampalis J; Ackad N; Conway B
    HIV Clin Trials; 2012; 13(4):179-88. PubMed ID: 22849960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.